```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1653HXP

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  FEB 27   New STN AnaVist pricing effective March 1, 2006
 NEWS  4  APR 04   STN AnaVist $500 visualization usage credit offered
 NEWS  5  MAY 10   CA/CAplus enhanced with 1900-1906 U.S. patent records
 NEWS  6  MAY 11   KOREAPAT updates resume
 NEWS  7  MAY 19   Derwent World Patents Index to be reloaded and enhanced
 NEWS  8  MAY 30   IPC 8 Rolled-up Core codes added to CA/CAplus and
                   USPATFULL/USPAT2
 NEWS  9  MAY 30   The F-Term thesaurus is now available in CA/CAplus
 NEWS 10  JUN 02   The first reclassification of IPC codes now complete in
                   INPADOC
 NEWS 11  JUN 26   TULSA/TULSA2 reloaded and enhanced with new search and
                   and display fields
 NEWS 12  JUN 28   Price changes in full-text patent databases EPFULL and PCTFULL
 NEWS 13  JUl 11   CHEMSAFE reloaded and enhanced
 NEWS 14  JUl 14   FSTA enhanced with Japanese patents
 NEWS 15  JUl 19   Coverage of Research Disclosure reinstated in DWPI
 NEWS 16  AUG 09   INSPEC enhanced with 1898-1968 archive
 NEWS 17  AUG 28   ADISCTI Reloaded and Enhanced
 NEWS 18  AUG 30   CA(SM)/CAplus(SM) Austrian patent law changes

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:02:52 ON 30 AUG 2006

=> file medline, uspatful, dgene, embase, wpids, fsta, jicst, hcaplus,
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
```

```
FULL ESTIMATED COST                                    1.05       1.05

FILE 'MEDLINE' ENTERED AT 18:05:55 ON 30 AUG 2006

FILE 'USPATFULL' ENTERED AT 18:05:55 ON 30 AUG 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 18:05:55 ON 30 AUG 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 18:05:55 ON 30 AUG 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 18:05:55 ON 30 AUG 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'FSTA' ENTERED AT 18:05:55 ON 30 AUG 2006
COPYRIGHT (C) 2006 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 18:05:55 ON 30 AUG 2006
COPYRIGHT (C) 2006 Japan Science and Technology Agency (JST)

FILE 'HCAPLUS' ENTERED AT 18:05:55 ON 30 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s screening method
   3 FILES SEARCHED...
L1        51826 SCREENING METHOD

=> s l1 and (protein target)
   3 FILES SEARCHED...
L2          300 L1 AND (PROTEIN TARGET)

=> s l2 and (methotrexate)
L3           81 L2 AND (METHOTREXATE)

=> s l3 and (methotrexate analog0
UNMATCHED LEFT PARENTHESIS 'AND (METHOTREXA'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s l3 and (methotrexate analog)
L4            1 L3 AND (METHOTREXATE ANALOG)

=> d l4 ti abs ibib tot

L4   ANSWER 1 OF 1  WPIDS  COPYRIGHT 2006 THE THOMSON CORP on STN
TI   New enzyme-cleavable conjugates comprising two receptor ligands useful in
     assays for screening proteins for the ability to catalyze bond cleavage.
AN   2002-147150 [19]   WPIDS
CR   2001-514515 [56]; 2004-440220 [41]
AB   US2002004202 A UPAB: 20040629
     NOVELTY - Enzyme-cleavable conjugates (I) comprising two receptor ligands
     are new.
          DETAILED DESCRIPTION - Conjugates of formula (I) are new:
          H1-X-B'-Y-H2    (I)
          H1, H2  = ligands capable of binding to the same or different
     receptors;
          X, Y  = spacer groups or are absent; and
          B'  = an enzyme-cleavable group.
          INDEPENDENT CLAIMS are also included for the following:
```

(1) conjugates of formula (II):

(2) complexes comprising (I) or (II) complexed to an enzyme;

(3) compositions comprising both (I) and (II);

(4) a method for screening proteins for the ability to catalyze bond cleavage, comprising:

(a) providing a cell that expresses a pair of fusion proteins which upon dimerization change a cellular readout;

(b) contacting the cell with a conjugate which dimerizes the pair of fusion proteins and comprises two portions coupled by a bond that is cleavable by the protein to be screened; and

(c) detecting any change in the cellular readout;

(5) a method for screening proteins for the ability to catalyze bond formation, comprising:

(a) providing a cell that expresses a pair of fusion proteins which upon dimerization change a cellular readout;

(b) contacting the cell with two compounds, each of which is capable of bonding to one of the fusion proteins and comprises a portion through which the compounds are coupled by the action of the protein to be screened; and

(c) detecting any change in the cellular readout;

(6) a method for screening a compound for the ability to inhibit an enzyme, comprising:

(a) screening for activity of the enzyme by method (4) or (5) to obtain cells that express an active enzyme; and

(b) contacting the cells with the compound to be screened;

(7) an enzyme-inhibiting drug selected by method (6);

(8) a method for evolving a protein with a new catalytic activity, comprising using method (4) or (5) to screen proteins from a library of proteins that are mutants of a known protein;

(9) a protein with a new catalytic activity evolved by method (8);

(10) a method for evolving an enzyme with a new substrate specificity, comprising using method (4) or (5) to screen enzymes from a library of enzymes that are mutants of an enzyme with known substrate specificity;

(11) an engineered enzyme with a new substrate specificity evolved by method (10);

(12) a method for evolving an enzyme that functions with a different cofactor from that of the corresponding natural enzyme, comprising:

(a) evolving mutants of the natural enzyme; and

(b) using method (4) or (5) to screen the mutants in the presence of a cofactor different from that of the natural enzyme;

(13) an engineered enzyme evolved by method (12);

(14) conjugates of formula (III):

(15) complexes of (III) and fusion proteins comprising a methotrexate binding domain;

(16) cells comprising the complexes of (15);

(17) a method for dimerizing two fusion proteins inside a cell, comprising contacting the cell with a conjugate (III) in which H1 binds to one of the proteins and H2 binds to the other;

(18) a method for identifying a molecule that binds a known target in a cell, comprising:

(a) covalently bonding each molecule in a pool of candidate molecules to methotrexate or a methotrexate analog to form screening molecules;

(b) introducing the screening molecules into cells that express a fusion protein with a methotrexate binding domain, a fusion protein comprising the known target, and a reporter gene whose expression is conditional on the proximity of the two fusion proteins;

(c) permitting the screening molecules to bind to the fusion proteins so as to activate expression of the reporter gene;

(d) selecting any cell in which the reporter gene is expressed; and

(e) identifying the molecule that binds the known target;

(19) a method for identifying a protein target to which a molecule is capable of binding, comprising:

(a) providing a screening molecule comprising methotrexate or a methotrexate analog covalently bonded to a ligand with specificity for an unknown protein target;

(b) introducing the screening molecule into a cell that expresses a fusion protein with a methotrexate binding domain, a fusion protein comprising the unknown protein target, and a reporter gene whose expression is conditional on the proximity of the two fusion proteins;

(c) permitting the screening molecules to bind to the fusion proteins so as to activate expression of the reporter gene;

(d) selecting any cell in which the reporter gene is expressed; and

(e) identifying the unknown protein target.

H1-X-B'' (II) H1-Y-H2 (III)

B'' = a molecule capable of binding to an enzyme.

H1 = methotrexate or a methotrexate analog;

H2 = a ligand capable of binding to a receptor; and

Y = a covalent bond or linker.

USE - (I) in which H1 and H2 are molecules capable of dimerizing fusion proteins are useful in a method for screening proteins for the ability to catalyze bond cleavage, comprising providing a cell that expresses a pair of fusion proteins which upon dimerization change a cellular readout, contacting the cell with (I), and detecting any change in the cellular readout.

Dwg.11/20

ACCESSION NUMBER: 2002-147150 [19] WPIDS
CROSS REFERENCE: 2001-514515 [56]; 2004-440220 [41]
DOC. NO. CPI: C2002-045569
TITLE: New enzyme-cleavable conjugates comprising two receptor ligands useful in assays for screening proteins for the ability to catalyze bond cleavage.
DERWENT CLASS: B05 D16
INVENTOR(S): CORNISH, V W
PATENT ASSIGNEE(S): (CORN-I) CORNISH V W
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2002004202	A1	20020110	(200219)*		48

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2002004202	A1 CIP of	US 2000-490320	20000124
		US 2001-768479	20010124

PRIORITY APPLN. INFO: US 2001-768479 20010124; US 2000-490320 20000124

=> d his

(FILE 'HOME' ENTERED AT 18:02:52 ON 30 AUG 2006)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, HCAPLUS' ENTERED AT 18:05:55 ON 30 AUG 2006

L1 51826 S SCREENING METHOD
L2 300 S L1 AND (PROTEIN TARGET)
L3 81 S L2 AND (METHOTREXATE)
L4 1 S L3 AND (METHOTREXATE ANALOG)

=> e cornish,v/au

```
E1          1     CORNISH WILLIAM G/AU
E2          1     CORNISH ZIRKER D/AU
E3          0 --> CORNISH,V/AU
E4          1     CORNISK ERIC H/AU
E5          1     CORNISKEY B/AU
E6          1     CORNIST K L/AU
E7          1     CORNIST KIM LAMAR/AU
E8          1     CORNISTA A/AU
E9          1     CORNISTA ANDREA/AU
E10         3     CORNISTA J/AU
E11         2     CORNISTA J C/AU
E12         4     CORNISTA JOEL/AU
```